ASAlexandra Smith

Alexandra Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandra Smith has a total of 252 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes

    by Dominic Culligan, Adele Taylor, Alexandra Smith, Catherine Cargo, Howard Oster, Argiris Symeonidis, Reinhard Stauder, Saskia Langemeijer, Luca Malcovati, Pierre Fenaux, et al.

    Objectives : To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower‐risk myelodysplastic syndromes. Methods : We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow‐up data in the prospective EUMDS study. Results : sEPO levels increase with WHO subtypes associated with erythroid hypoplasia and poorer risk IPSS‐R scores. sEPO is an independent predictor of transfusion free survival and levels < 200 IU/L predict response to ESA. sEPO is not an independent predictor of overall survival. Conclusions : sEPO predicts transfusion free survival and response to ESA. Trial Registration : The EUMDS Registry (ClinicalTrials.gov: Identifier NCT00600860).

  • Open Access

    Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network

    by Eleanor Kane, Alexandra Smith, Debra Howell, Catherine Cargo, Kate Rothwell, Simone Green, Russell Patmore, Eve Roman

    Outcomes among patients with chronic myeloid leukaemia (CML) improved markedly when tyrosine kinase inhibitors (TKIs) were introduced into routine clinical practice around the turn of the century. Nonetheless, adverse events still occur, survival remains suboptimal and the long‐term health impact of the disease and its treatment is poorly understood. Using data from an established UK population‐based cohort of haematological malignancies, we compared the morbidity of 411 CML patients treated with TKIs 2009–2019 to that of individually age‐ and sex‐matched general population‐based controls ( n = 4099). Over the course of follow‐up (to March 2021, median 5.3, interquartile range 3.0–8.2 years), patients were more likely than controls to die from cardiovascular or respiratory diseases; Hazard Ratios of 1.9, 95% Confidence Interval, 95% CI = 1.2–2.8 and 2.4, 95% CI 1.2–4.9 respectively. Hospital admissions for cardiovascular or respiratory conditions were similarly elevated; HR = 1.6, 95% CI 1.3–1.9; HR = 2.3, 95% CI 1.6–3.4 respectively. The risk of a cardiovascular admission varied over time; being increased in the first year (HR = 2.4, 95% CI 1.5–3.8), and then again 5 years or more after starting TKI therapy (HR = 2.3, 95% CI 1.5–3.6); no increase was evident in the intervening years (HR = 1.1, 95% CI 0.8–1.7). While not related to excess mortality, admissions for infections and gastrointestinal conditions occurred more frequently among cases than controls; the increased risk remaining largely constant over the course of follow‐up. In the era of TKIs, these real‐world analyses revealed that CML patients are at increased risk of severe cardiovascular events several years after starting treatment, and that admission for infections and gastrointestinal conditions are raised throughout.

  • Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

    by Aleksandar Savic, Adele Taylor, Pierre Fenaux, Argiris Symeonidis, Catherine Cargo, Moshe Mittelman, Verena Petzer, Guillermo Sanz, Jaroslav Čermák, Saskia Langemeijer, et al.

    Summary: Selecting eligible allogeneic haematopoietic stem cell transplantation (allo‐HSCT) candidates with low‐risk and intermediate‐risk myelodysplastic syndrome (MDS) remains controversial. The International Working Group (IWG) for MDS prognosis identified a Revised International Prognostic Scoring System (IPSS‐R) score >3.5 for benefits from early transplantation; the MDS‐RIGHT group uses a broader set of poor risk features. We analysed 1145 lower risk MDS (lower risk and intermediate‐risk IPSS‐R) patients aged <75 years, using real‐world European Myelodysplastic Syndromes registry data and identifying those meeting IWG or MDS‐RIGHT criteria for allo‐HSCT at baseline and 6‐month follow‐up. Fit patients were characterised by Karnofsky score ≥70 and Haematopoietic Cell Transplantation‐specific Comorbidity Index <3. We evaluated clinical outcomes of transplant candidates, including survival, disease progression risk, new comorbidity risk and performance status decline. The IWG criterion, and not MDS‐RIGHT criteria, identified patients with lower risk and intermediate‐risk MDS with poorer baseline survival. Fit lower risk patients showed 2‐year cumulative risks of incident comorbidity and performance status deterioration of 20% and 5% respectively. In summary, IWG and MDS‐RIGHT features identify patients with lower or intermediate‐risk MDS as candidates for early transplantation. Lower risk patients fit for transplantation have a cumulative incidence of adverse outcomes possibly jeopardising transplantation eligibility and should be carefully selected when planning delayed transplantation strategies.


  • Open Access

    Patient and Public Involvement and Engagement within a UK blood cancer cohort: a case study

    by Debra Howell, Carol Miller, Amy Rebane, Rebecca Sheridan, Eve Roman, Alexandra Smith

    This paper presents a case study of Patient and Public Involvement (PPI), in which people shared their ‘lived experience’ as ‘experts’ who manage their blood cancer on a daily basis, within their own environment and social circumstances. The case study is set within an ongoing cohort study that was established in 2004 in the North of England, and currently includes ~ 55,000 newly diagnosed patients (no exclusions), increasing annually by ~ 2,500. Participants are invited to join a Patient Partnership, and if they agree may be asked to take part in PPI. PPI is conducted with selected patients, matched to the research question. It takes place during one-to-one or group consultations (interviews or focus groups), which may occur face-to-face or online, and during the daytime or evening, on a weekday or weekend, to provide various options and promote inclusivity. PPI meetings have generated advice on research priorities, website design and content, and study design and implementation; with more formal collaborations established within funding applications, and Oversight Committee and Sub-Committees. Researchers received practical assistance in preparing clear study paperwork written in plain language, for information leaflets and consent forms, academic papers, and summaries used to share findings on lay-websites and social media sites. Letters of support have also been provided for funding applications. PPI has underpinned the cohort’s ethical and governance approvals; and improved its methods, and the way in which findings are shared. Open Days and other meetings with patients and the public have raised awareness about the cohort and engaged people in the research process. People said they were pleased to take part in PPI and to have the opportunity to give something back. Factors for success were the inclusion of appropriate stakeholders, sufficient reimbursement, feedback on impact, skilled facilitators, and good governance. PPI activities will be strengthened within the cohort over coming years, by significant expansion in members of the Oversight Committee and Sub-Committees, from across the study area, and with an increased focus on underserved communities. Effective PPI requires sufficient time, skills, effort and resources; and it is important to be aware of changes in this rapidly developing area.

  • COVID ‐19‐related mortality in a real‐world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK 's Haematological Malignancy Research Network

    by Alexandra Smith, Clare Frobisher, Abraham Varghese, Andy Rawstron, Simon Crouch, Debra Howell, Adele Fielding, Kirstine Eastick, Catherine Cargo, Cathy Burton, et al.

    Summary: When the World Health Organization (WHO) declared the global COVID‐19 pandemic, it was recognised that patients with haematological cancers would be more susceptible to severe disease. Set within a UK population of ~4 million ( https://hmrn.org/ ), all patients diagnosed with haematological neoplasms 2005–2019 who were alive on 1 January 2020 were followed up until March 2023. For comparative purposes, a similar age‐ and sex‐matched general population cohort was also constructed. COVID‐19 deaths were classified using ICD‐10 codes and a multiple cause of death analysis was undertaken using a competing risk approach. Deaths of 486/18 883 haematology patients were attributed to COVID‐19, yielding a cumulative incidence of 2.59% (95% confidence interval [CI]: 2.37–2.82) that was significantly higher than that of the general population (1.65; 95% CI: 1.58–1.72). In both cohorts, risks were higher in men, older people and those with co‐morbidities. Within the patient cohort, excess mortality was largely concentrated in those suffering from more indolent conditions. Patients with the premalignancy MBL suffered from the highest excess mortality in the early phase of the pandemic when, unlike patients with malignancies, they were not advised to shield. Effects of shielding were evident and a clear vaccination benefit was demonstrated, with the exception of CLL and MCL; findings that warrant consideration in relation to other viruses.


  • Open Access

    Mapping VEXAS ‐associated and rare UBA1 variants in the United Kingdom : Insights from patient cohorts and the general population

    by Ana Martinez Rodriguez, Leon Chang, Dorota Rowczenio, Alexandra Smith, Ebun Omoyinmi, James A. Poulter, Andrew McGregor, Sebastian Francis, Roochi Trikha, Adam Al‐Hakim, et al.

    Summary: Somatic mutations in UBA1 are linked to VEXAS syndrome, a late‐onset inflammatory disorder with rheumatological and haematological features, primarily affecting elderly men. This study examines the epidemiology of VEXAS in the United Kingdom using genomic databases and patient cohorts to estimate prevalence, identify novel UBA1 variants and predict their pathogenicity. Analysing data from the UK Biobank, 100 000 Genomes Project and clinical diagnostic laboratories, we found that VEXAS prevalence in UK males over 50 is lower than in US‐based cohorts. Notably, canonical (Met41) UBA1 mutations appear in ~1% of individuals with autoinflammatory disorders who have not been referred to haematology. However, among those investigated for myeloid malignancies, VEXAS is relatively common, with an estimated incidence of 1.51 per 100 000, or 171 new cases each year. We identified 47 UBA1 non‐Met41 variants of uncertain significance, with several showing clonal dominance and clustering in functional domains, suggesting potential pathogenicity. Clinical presentation associated with non‐Met41 variants often diverged from classical VEXAS features, underscoring the need for further studies. Our findings highlight the importance of broader screening for both canonical and non‐canonical UBA1 mutations to improve understanding of VEXAS syndrome and its underlying mechanisms.


  • Open Access

    Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK’s Haematological Malignancy Research Network

    by Alexandra Smith, Timothy Bagguley, Eve Roman, Simon Crouch, Russell Patmore, Ruth De Tute, Andy Rawstron, Gordon Cook, Frances Seymour, Christopher Parrish


  • Open Access

    Inflammatory profile of lower risk myelodysplastic syndromes

    by Joanne Topping, Adele Taylor, Fatima Nadat, Simon Crouch, Alice Ibbotson, Jaroslav Čermák, Argiris Symeonidis, Aurelia Tatic, Saskia Langemeijer, Eva Hellström‐Lindberg, et al.

    Summary: The precise link between inflammation and pathogenesis of myelodysplastic syndrome (MDS) is yet to be fully established. We developed a novel method to measure ASC/NLRP3 protein specks which are specific for the NLRP3 inflammasome only. We combined this with cytokine profiling to characterise various inflammatory markers in a large cohort of patients with lower risk MDS in comparison to healthy controls and patients with defined autoinflammatory disorders (AIDs). The ASC/NLRP3 specks were significantly elevated in MDS patients compared to healthy controls (p < 0.001) and these levels were comparable to those found in patients with AIDs. The distribution of protein specks positive only for ASC was different to ASC/NLRP3 ones suggesting that other ASC‐containing inflammasome complexes might be important in the pathogenesis of MDS. Patients with MDS‐SLD had the lowest levels of interleukin (IL)‐1β, tumour necrosis factor (TNF), IL‐23, IL‐33, interferon (IFN) γ and IFN‐α2, compared to other diagnostic categories. We also found that inflammatory cytokine TNF was positively associated with MDS progression to a more aggressive form of disease and IL‐6 and IL‐1β with time to first red blood cell transfusion. Our study shows that there is value in analysing inflammatory biomarkers in MDS, but their diagnostic and prognostic utility is yet to be fully validated.


  • Open Access

    Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network

    by Maxine Lamb, Daniel Painter, Debra Howell, Sharon Barrans, Catherine Cargo, Ruth de Tute, Reuben Tooze, Cathy Burton, Russell Patmore, Eve Roman, et al.


  • Open Access

    Cohort profile: the United Kingdom Childhood Cancer Study (UKCCS) – a UK-wide population-based study examining the health of cancer survivors

    by Eve Roman, Eleanor Kane, Alexandra Smith, Debra Howell, Rebecca Sheridan, Jill Simpson, Audrey Bonaventure, Sally Kinsey

    Purpose The United Kingdom Childhood Cancer Study’s (UKCCS’s) matched cohort was established to examine the longer term morbidity and mortality of individuals previously diagnosed with cancer before 15 years of age, comparing future healthcare patterns in 5-year cancer survivors to baseline activity seen in age- and sex-matched individuals from the general population. Participants Predicated on a national childhood cancer case-control study conducted in the early 1990s (4430 cases, 9753 controls) in England, Scotland and Wales, the case population comprises 3125 cancer survivors (>5 years), and the control population 7156 age- and sex-matched individuals from the general population who did not have cancer as a child. Participants are now being followed up via linkage to national administrative healthcare databases (deaths, cancers and secondary care hospital activity). Findings to date Enabling the creation of cohorts with minimal selection bias and loss to follow-up, the original case-control study registered all newly diagnosed cases of childhood cancer and their corresponding controls, regardless of their family’s participation. Early findings based on the registered case population found marked survival variations with age and sex across subtypes and differences with deprivation among acute lymphoblastic leukaemia (ALL) survivors. More recently, comparing the health-activity patterns of the case and control populations revealed that survivors of childhood ALL experienced excess outpatient and inpatient activity across their teenage/young adult years. Adding to increased risks of cancer and death and involving most clinical specialties, excesses were not related to routine follow-up monitoring and showed no signs of diminishing over time. Future plans With annual linkage updates, the UKCCS’s maturing population-based matched cohorts provide the foundation for tracking the health of individuals through their lifetime. Comparing the experience of childhood cancer survivors to that of unaffected general-population counterparts, this will include examining subsequent morbidity and mortality, secondary care hospital activity and the impact of deprivation on longer term outcomes.